Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Probi AB
Probi's probiotic "significantly decreased" plasma levels of two inflammatory markers coupled to acute stress in study, with the firm planning further research into the gut-brain axis.
EU Business Round-Up: Probi Targets Acquisitions, Oystershell Heads To US, Doetsch Grether Inks Swiss Deal
Probiotics player Probi will use deals and organic growth to double its sales over five years; Belgium's Oysershell strikes deal with Bayer for head-lice brand; and Doetsch Grether acquires Swiss supplements firm Vita.
With its focus firmly on oncology, the Swedish biotech, and its outgoing chief, believe the company now needs someone with more scientific skills in the CEO role.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.
- OTC, Consumer